Unlike traditional chemotherapy, the EV+pembrolizumab combination is producing a "tail on the curve" in survival data. This indicates a significant minority of patients with metastatic bladder cancer are achieving durable, long-term responses—a phenomenon previously unseen and a paradigm shift for the disease.

Despite multiple clinical trials, adding checkpoint inhibitors to frontline therapy for ovarian cancer has not demonstrated a proven survival benefit. The role of immunotherapy in this setting remains confined to rare subsets like DMMR or TMB-high tumors, and it is not standard practice for the general population.

After numerous failed trials suggested immunotherapy was ineffective in ovarian cancer, the KEYNOTE B96 study marks a turning point. Combining pembrolizumab with chemotherapy showed statistically significant improvements in both progression-free and overall survival in platinum-resistant patients, reviving the entire therapeutic class for this disease.

The B96 trial's positive outcome in historically immunotherapy-resistant ovarian cancer is not just about adding pembrolizumab. The regimen's success is attributed to the thoughtful use of continuous weekly paclitaxel, a form of metronomic chemotherapy known to have favorable immunogenic effects, which was a deliberate, science-backed choice.

After a decade with no new therapies improving survival, the landscape for platinum-resistant ovarian cancer is transforming. The recent successes of mirvetuximab, the pembrolizumab/paclitaxel combo, and relacorilant/nab-paclitaxel have all demonstrated statistically significant overall survival benefits, heralding a new era of effective options.

The future of GYN oncology immunotherapy is diverging. For responsive cancers like endometrial, the focus is on refining biomarkers and overcoming resistance. For historically resistant cancers like ovarian, the strategy shifts to using combinatorial approaches (e.g., CAR-NKs, vaccines) to fundamentally alter the tumor microenvironment itself, making it more receptive to an immune response.

Dr. Carbone argues that traditional metrics like median survival or response rate are less relevant for immunotherapies. The true measure of success is the percentage of patients alive at five or six years—the "tail of the curve"—as this indicates a durable, potentially curative, response.

The success of the KEYNOTE-B96 trial highlights weekly paclitaxel as a uniquely effective partner for immunotherapy in platinum-resistant ovarian cancer. Its metronomic dosing modulates the tumor microenvironment, enhances immunogenicity, and reduces immunosuppression, making it superior to other chemotherapies in this combination.

Immunotherapies can be effective even without causing significant tumor shrinkage. Immunocore's drug KimTrack had a low 5-7% objective response rate (ORR) but demonstrated a massive overall survival (OS) benefit, challenging the reliance on traditional chemotherapy metrics for evaluating modern cancer treatments.